TACOME试验中的经动脉放射性栓塞:剂量学分析与临床特征预测缓解和总生存
这项多中心回顾性研究纳入176例接受90Y玻璃微球治疗的结直肠癌肝转移患者,用99mTc-MAA SPECT计算剂量学参数并以18F-FDG PET评估缓解。平均估计肿瘤吸收剂量与缓解强相关,预测缓解的阈值为152 Gy,高于152 Gy者中位总生存18.1个月优于其余患者的12.8个月。
要点
- 平均估计肿瘤吸收剂量预测缓解的阈值为152 Gy,灵敏度93%、特异度89%、AUC 0.945。
- 平均估计灌注体积吸收剂量预测缓解的阈值为109 Gy,灵敏度68%、特异度73%、AUC 0.728。
- 平均估计肿瘤吸收剂量高于152 Gy者中位总生存18.1个月,其余患者为12.8个月。
核心结论
- 作者认为肿瘤平均辐射剂量至少152 Gy可能预测代谢缓解。
- 152 Gy阈值虽预测更长总生存,但平均估计肿瘤吸收剂量达203 Gy时可预测比低于203 Gy者更长的总生存。
研究设计与样本
- 多中心回顾性研究,纳入接受90Y玻璃微球治疗的转移性结直肠癌患者176例(男112例、女64例)。
- 用99mTc-大颗粒聚合白蛋白SPECT图像计算平均灌注体积、平均估计灌注体积吸收剂量、平均估计肿瘤吸收剂量、平均估计灌注正常肝吸收剂量和平均估计全肝吸收剂量。
- 用18F-FDG PET图像评估治疗至缓解。
主要发现
- 平均估计肿瘤吸收剂量与治疗缓解呈强相关(P=0.001)。
- 预测缓解的截断值:平均估计灌注体积吸收剂量109 Gy(灵敏度68%、特异度73%、AUC 0.728、P=0.001),平均估计肿瘤吸收剂量152 Gy(灵敏度93%、特异度89%、AUC 0.945、P=0.001)。
- 平均估计肿瘤吸收剂量高于152 Gy者中位总生存18.1个月(95%CI 15.7-20.4个月),其余患者12.8个月(95%CI 10.6-15.0个月),P=0.030。
- 用最大选择秩统计量进一步分析显示,平均估计肿瘤吸收剂量最低203 Gy者总生存比更低者长6.4个月(P=0.022)。
关键数值与推荐
- 平均估计肿瘤吸收剂量152 Gy预测代谢缓解:灵敏度93%、特异度89%、AUC 0.945、P=0.001。
- 平均估计灌注体积吸收剂量109 Gy预测缓解:灵敏度68%、特异度73%、AUC 0.728、P=0.001。
- 平均估计肿瘤吸收剂量高于152 Gy者中位总生存18.1个月(95%CI 15.7-20.4个月) vs 其余患者12.8个月(95%CI 10.6-15.0个月),P=0.030。
- 平均估计肿瘤吸收剂量最低203 Gy者总生存比更低者长6.4个月(P=0.022)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this multicenter retrospective study, we aimed to analyze the dose-response and survival relationships and estimate the tumor absorbed radiation dose required to achieve response in colorectal cancer liver metastases treated with 90Y glass microspheres. Methods: Patients with metastatic colorectal cancer treated with 90Y glass microspheres were included in this retrospective study. Mean perfused volume, mean estimated perfused volume absorbed dose, mean estimated tumor absorbed dose (ETAD), mean estimated perfused normal liver absorbed dose, and mean estimated whole liver absorbed dose were calculated using [99mTc]-macroaggregated albumin SPECT images. Treatment to response was evaluated by [18F]-FDG PET images. Results: In total, 176 patients (112 men and 64 women) were included in the analysis. A strong correlation was found between mean ETAD and response to treatment (P = 0.001). The cutoff values to predict a response were calculated as 109 Gy (sensitivity, 68%; specificity, 73%; area under the curve, 0.728; P = 0.001) for mean estimated perfused volume absorbed dose and 152 Gy (sensitivity, 93%; specificity, 89%; area under the curve, 0.945; P = 0.001) for mean ETAD. The median overall survival (OS) of patients with a mean ETAD higher than 152 Gy was significantly longer than that of the remaining patients, at 18.1 mo (95% CI, 15.7-20.4 mo) versus 12.8 mo (95% CI, 10.6-15.0 mo; P = 0.030). Further analysis using maximally selected rank statistics to better predict OS showed that patients with a minimum mean ETAD of 203 Gy had OS 6.4 mo longer than the OS of those with a lower mean ETAD (P = 0.022). Conclusion: A mean radiation dose to the tumor of at least 152 Gy may predict a metabolic response. Although a threshold of 152 Gy predicted longer OS, a mean ETAD of 203 Gy, when achievable, predicted even longer OS than found for those with a mean ETAD of less than 203 Gy.
引用
- Soydal C, Araz M, Demir B, et al. Transarterial Radioembolization in the TACOME Trial: Dosimetric Analysis and Clinical Features in Predicting Response and Overall Survival. J Nucl Med. 2025. PMID: 40404391. doi:10.2967/jnumed.125.269519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。